Why N-13 Ammonia

N-13 Ammonia paves the way to better diagnostics with a low positron range, excellent extraction and retention, high sensitivity and overall accuracy for detecting CAD.1 The result is better risk classification and overall patient management.

Providing high diagnostic accuracy in all patient types, N-13 Ammonia is used in a growing number of major academic institutions and is rapidly changing the standard of excellence for Cardiac PET imaging.

1 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382649/

Superior Image Quality1

While Cardiac PET has been shown to be superior to SPECT, not all tracers are equal. Considered an optimal tracer for myocardial perfusion imaging, N-13 Ammonia provides:

  • High spatial and contrast resolution images
  • High first-pass extraction and retention in the myocardium
  • Consistently high-quality diagnostic studies regardless of patient size or gender

1. Fiechter et al., J Nucl Med 2012; 53: 1230-1234

Expanded Testing Options

Due to a longer half-life, N-13 Ammonia may allow for testing options not possible with other FDA-approved tracers.

Recent studies utilizing treadmill N-13 Ammonia stress testing have demonstrated:

N-13 Ammonia v. Rb-82 Chloride

Due to the short positron range before the proton annihilation, N-13 Ammonia is capable of intrinsically high spatial resolution, which can lead to improved diagnostic clarity.

View comparison chart

N-13 Ammonia v. Rb-82 Chloride Comparison

Physical properties 2 N-13 Ammonia Rb-82 Chloride
Half life (min) 9.97 1.27
Positron decay 100% 95.5%
Positron range (mm) 0.57 2.60
Image Resolution (mm) FWHM 5 8
Effective radiation (mSv/MBq) 0.002 0.0034
Raw material High Purity O-16 water and methane gas Sr-82/Sr-85
Supplied Unit Dose Generator
Physiological properties 1 N-13 Ammonia Rb-82 Chloride
Physiology Diffusible/retained Extracted/retained
  Rest Stress Rest Stress
Extraction fraction 0.98 0.93 0.70 0.40
Retention fraction 0.87-0.97 0.56-0.65 0.47-0.55 0.27-0.28
  1. deKemp et. al. “Will 3-dimensional PET-CT enable the routine quantification of myocardial blood flow?” J. Nucl Cardiol 2007; 14:380-97
  2. Sabin, MG, Radiopharmaceuticals for Nuclear Cardiology: Radiation Dosimetry, Uncertainties, and Risk, J Nucl Med 2008; 49:1555-1563


Reimbursement is critical to the financial viability of any Cardiac PET program. N-13 Ammonia is FDA-approved and reimbursed by Medicare and most private payers. Plus, IONETIX stands ready to help you navigate the reimbursement process so you can focus on what you do best: delivering the best care possible.


Prescribing Information

N-13 Ammonia Injection is a radioactive diagnostic agent for Positron Emission Tomography (PET) indicated for diagnostic PET imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease.

None known.

No adverse reactions have been reported for N-13 Ammonia Injection based on a review of the published literature, publicly available reference sources, and adverse drug reaction reporting system.

N-13 Ammonia Injection may increase the risk of cancer. Use the smallest dose necessary for imaging and ensure safe handling to protect the patient and health care worker.

Full prescribing information is available for download here

Ready to elevate your cardiac imaging PET program? CLICK HERE!

Copyright © Ionetix Corporation